Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Innovations for vaccines against helminth infections

Project description

Developing the next-gen of worm vaccines

Parasitic worm infections affect hundreds of millions of people worldwide and cause chronic illness, impaired development, and economic loss. Effective vaccines are still lacking. Target discovery methods and tailored production and testing pipelines are needed to support next-generation helminth vaccines. The EU-funded WORMVACS2.0 project aims to establish a comprehensive vaccine development pipeline for schistosomes and hookworms. It will use human infection models, advanced animal studies, and innovative antigen platforms to shed light on protective immune signatures. Its efforts include a phase 1 trial of an mRNA-based schistosomiasis vaccine, paving the way for new tools to control and eliminate these persistent Neglected tropical diseases.

Objective

Infections with parasitic worms (helminths) continue to cause a massive global health burden. Yet, effective vaccines to enable control and elimination of helminth infections do not exist. Primary reasons for this are that target discovery approaches are not well-developed, protective immune mechanisms are only partially clarified at best, production platforms tailored to specific helminth vaccine requirements are not available, and a pipeline for selecting and rapidly progressing pre-clinical and clinical vaccine candidates is generally lacking. Moreover, controlled human infection models are only now being developed and optimized for some of the most important human helminths. These models have not yet been widely implemented in vaccine development programs to date.

The objective of WORMVACS2.0 is to establish an effective pipeline to support helminth vaccine development focusing on schistosomes and hookworms, and ultimately the control and elimination of some of the world’s most devastating and persistent Neglected Tropical Diseases (NTDs). We aim to achieve this through the development and application of an innovative approach leveraging controlled human infection models, novel platforms for helminth vaccine/vaccine antigen production, experimental animal models, and improved target discovery methodology applying state-of-the-art immunological profiling to identify correlates and signatures of protection.

WORMVACS2.0 will advance scientific and clinical knowledge of host immunity in response to helminth infection, apply innovative and sustainable platform technologies tailored to the next generation of effective vaccines against helminth infections of global importance. The project will produce a diversified portfolio of hookworm and schistosome vaccine candidates ready for progressing to clinical testing and conduct a phase 1 clinical trial to advance an mRNA platform based schistosomiasis vaccine.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-RIA - HORIZON Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-HLTH-2022-DISEASE-06-two-stage

See all projects funded under this call

Coordinator

ACADEMISCH ZIEKENHUIS LEIDEN
Net EU contribution
€ 2 554 517,25
Address
ALBINUSDREEF 2
2333 ZA Leiden
Netherlands
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 2 554 517,25

Participants (8)

Partners (4)